Eli Lilly: Market cap $679.93 billion Johnson & Johnson: Market cap $370.20 billion AbbVie: Market cap $312.75 billion Novo Nordisk: Market cap $287.03 billion Roche: Market cap $250.29 billion ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

"European price controls and austerity measures reduce the attractiveness of its markets," Novartis CEO Vas Narasimhan and ...

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is ...

Big Pharma, long a lobbying powerhouse in Washington, is struggling to settle on a strategy for defending itself against ...

US market exposure limits Indian pharma's safe-haven appeal amid global volatility and tariff fears, but drugmakers focused on domestic markets can officer investors a potential hedge against uncertai ...

About 30% of Big Pharma acquisitions involving ... Then, we picked companies with a 5-year revenue growth of 10% and ranked the top 10 based on hedge fund sentiment as of Q4 2024, as per Insider ...

Pharma companies are leveraging the United States ... These include increasing Europe's regulatory data protection baseline to 10 years, plus an additional two years of market protection ...

In this backdrop, shares of pharma companies have taken a hit. Since 2 April close, shares of Biocon and Aurobindo have lost about 10% and 8.6% whereas the stock of Dr Reddy’s is down 4.9%.

Pharmaceutical companies in recent decades moved production ... A Reuters review found that Medicare's recently-negotiated prices for its 10 most costly drugs are still more than double, and ...

Analysis-Pharma Companies Expected to Absorb Any Tariff ... A Reuters review found that Medicare's recently-negotiated prices for its 10 most costly drugs are still more than double, and in ...